Adaptive Biotechnologies Corp
ADPT
Market Cap$338.79M
Close$
$3.64
40% upside
Current Fair Value
40% upsideUndervalued by 40% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $338.79 Million |
|---|---|
| Enterprise Value | $-7,610,547.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.56 |
| Beta | 1.96 |
| Outstanding Shares | 145,092,271 |
| Avg 30 Day Volume | 2,174,577 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.5 |
|---|---|
| PEG | -2.06 |
| Price to Sales | 2.6 |
| Price to Book Ratio | 1.3 |
| Enterprise Value to Revenue | -0.04 |
| Enterprise Value to EBIT | 0.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...